Predicting Disease Activity in Rheumatoid Arthritis With the Fibromyalgia Survey Questionnaire: Does the Severity of Fibromyalgia Symptoms Matter?
- PMID: 36521924
- PMCID: PMC10159881
- DOI: 10.3899/jrheum.220507
Predicting Disease Activity in Rheumatoid Arthritis With the Fibromyalgia Survey Questionnaire: Does the Severity of Fibromyalgia Symptoms Matter?
Abstract
Objective: To determine if the degree of baseline fibromyalgia (FM) symptoms in patients with rheumatoid arthritis (RA), as indicated by the Fibromyalgia Survey Questionnaire (FSQ) score, predicts RA disease activity after initiation or change of a disease-modifying antirheumatic drug (DMARD).
Methods: One hundred ninety-two participants with active RA were followed for 12 weeks after initiation or change of DMARD therapy. Participants completed the FSQ at the initial visit. The Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) was measured at baseline and follow-up to assess RA disease activity. We evaluated the association between baseline FSQ score and follow-up DAS28-CRP. As a secondary analysis, we examined the relationship between the 2 components of the FSQ, the Widespread Pain Index (WPI) and Symptom Severity Scale (SSS), with follow-up DAS28-CRP. Multiple linear regression analyses were performed, adjusting for clinical and demographic variables.
Results: In multiple linear regression models, FSQ score was independently associated with elevated DAS28-CRP scores 12 weeks after DMARD initiation (B = 0.04, P = 0.01). In secondary analyses, the WPI was significantly associated with increased follow-up DAS28-CRP scores (B = 0.08, P = 0.001), whereas the SSS was not (B = -0.03, P = 0.43).
Conclusion: Higher levels of FM symptoms weakly predicted worse disease activity after treatment. The primary factor that informed the FSQ's prediction of disease activity was the spatial extent of pain, as measured by the WPI.
Keywords: disease activity; fibromyalgia; rheumatoid arthritis.
Copyright © 2023 by the Journal of Rheumatology.
Conflict of interest statement
YCL, LNM, and JS were supported by NIH/NIAMS P30 AR072579. YCL has also received research support from Pfizer, consulted for Sanofi Genzyme (<$10,000), and has stock in Cigna. MBB has received grant funding from the Rheumatology Research Foundation, clinical trials support from Genentech, and honoria from the American Board of Internal Medicine and Merck Manual, respectively. She is an associate editor for PracticeUpdate and Advanced Rheumatology Course (ACR/ARP). COB receives support from NIH (AR070254).
Similar articles
-
Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis.Arthritis Rheum. 2009 Jun 15;61(6):794-800. doi: 10.1002/art.24430. Arthritis Rheum. 2009. PMID: 19479706
-
Ultrasound Assessment of Disease Activity Prevents Disease-Modifying Antirheumatic Drug (DMARD) Escalation and May Reduce DMARD-Related Direct Costs in Rheumatoid Arthritis With Fibromyalgia: An Exploratory Study.J Ultrasound Med. 2020 Jul;39(7):1271-1278. doi: 10.1002/jum.15215. Epub 2020 Jan 20. J Ultrasound Med. 2020. PMID: 31958164
-
The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.Clin Rheumatol. 2019 Nov;38(11):3081-3092. doi: 10.1007/s10067-019-04649-4. Epub 2019 Jul 29. Clin Rheumatol. 2019. PMID: 31353421
-
The DAS28 in rheumatoid arthritis and fibromyalgia patients.Rheumatology (Oxford). 2004 Dec;43(12):1504-7. doi: 10.1093/rheumatology/keh322. Epub 2004 Jul 13. Rheumatology (Oxford). 2004. PMID: 15252215
-
Non-inflammatory pain in inflammatory arthritis.Rheumatology (Oxford). 2023 Jul 5;62(7):2360-2365. doi: 10.1093/rheumatology/keac671. Rheumatology (Oxford). 2023. PMID: 36478185 Free PMC article. Review.
References
-
- Einarsson JT, Willim M, Ernestam S, Saxne T, Geborek P, Kapetanovic MC. Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden. Rheumatology 2019;58:227–36. - PubMed
-
- Uhlig T, Lie E, Norvang V, Lexberg ÅS, Rødevand E, Krøll F, et al. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study. J Rheumatol 2016;43:716–23. - PubMed
-
- Wijbrandts CA, Tak PP. Prediction of Response to Targeted Treatment in Rheumatoid Arthritis. Mayo Clin Proc 2017;92:1129–43. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous